Nectar Therapeutics sell-off seen as overdone
The guest argued that Nectar's recent stock decline is an overreaction to transient headwinds like litigation and perceived competition, leaving the underlying asset undervalued.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.